Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
5.6
Journals
IJMS
Special Issues
From Molecular Insights to Novel Clinical Perspectives in Adrenocortical Cancer
ijms-logo
Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

From Molecular Insights to Novel Clinical Perspectives in Adrenocortical Cancer

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 4215

Special Issue Editors

Prof. Dr. Maria Candida Barisson Vilares Fragoso

E-Mail Website
Guest Editor
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), Instituto do Câncer do Estado de São Paulo (ICESP), São Paulo 05466-040, Brazil
Interests: adrenocortical tumor benign; malignant adrenal disorders
Dr. Antonio Marcondes Lerario

E-Mail Website
Guest Editor
Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, MI 48109, USA
Interests: adrenocortical cancer; bioinformatic analysis

Special Issue Information

Dear Colleagues,

Adrenocortical carcinoma (ACC) is rare and extremely aggressive malignancy with heterogeneous clinical presentation and outcomes. Despite a profound increase in our knowledge about the molecular pathogenesis of ACC over the last few decades, therapies for advanced disease remain limited to few systemic agents and are largely ineffective. This Special Issue features experts from different areas of ACC research, with the broad goal of discussing new strategies to advance patient care by incorporating conceptual advances from basic science to translational and clinical research. Novel translational aspects and therapeutic approaches, including the molecular stratification of ACC, the role of molecular biomarkers, animal models, preclinical studies, ongoing clinical trials, adjuvant and neoadjuvant therapies, and advances in surgical management and locoregional approaches are covered in this series. We hope to provide novel insights and perspectives that will narrow the knowledge gap towards individualized and effective therapies that hopefully will improve the survival and quality of life of ACC patients in the near future.

Prof. Dr. Maria Candida Barisson Vilares Fragoso
Dr. Antonio Marcondes Lerario
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • adrenocortical cancer
  • ACC
  • prognostic factors
  • metastasis
  • liquid biopsy
  • urinary

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

17 pages, 4592 KiB  
Article
Preclinical Evidence of Progesterone as a New Pharmacological Strategy in Human Adrenocortical Carcinoma Cell Lines
by Mariangela Tamburello, Andrea Abate, Elisa Rossini, Ram Manohar Basnet, Daniela Zizioli, Deborah Cosentini, Constanze Hantel, Marta Laganà, Guido Alberto Massimo Tiberio, Salvatore Grisanti, Maurizio Memo, Alfredo Berruti and Sandra Sigala
Int. J. Mol. Sci. 2023, 24(7), 6829; https://doi.org/10.3390/ijms24076829 - 6 Apr 2023
Cited by 4 | Viewed by 1870
Abstract
Background: Adrenocortical cancer (ACC) is a rare malignancy with a dismal prognosis. The treatment includes mitotane and EDP chemotherapy (etoposide, doxorubicin, and cisplatin). However, new therapeutic approaches for advanced ACC are needed, particularly targeting the metastatic process. Here, we deepen the role of [...] Read more.
Background: Adrenocortical cancer (ACC) is a rare malignancy with a dismal prognosis. The treatment includes mitotane and EDP chemotherapy (etoposide, doxorubicin, and cisplatin). However, new therapeutic approaches for advanced ACC are needed, particularly targeting the metastatic process. Here, we deepen the role of progesterone as a new potential drug for ACC, in line with its antitumoral effect in other cancers. Methods: NCI-H295R, MUC-1, and TVBF-7 cell lines were used and xenografted in zebrafish embryos. Migration and invasion were studied using transwell assays, and MMP2 activity was studied using zymography. Apoptosis and cell cycle were analyzed by flow cytometry. Results: Progesterone significantly reduced xenograft tumor area and metastases formation in embryos injected with metastatic lines, MUC-1 and TVBF-7. These results were confirmed in vitro, where the reduction of invasion was mediated, at least in part, by the decrease in MMP2 levels. Progesterone exerted a long-lasting effect in metastatic cells. Progesterone caused apoptosis in NCI-H295R and MUC-1, inducing changes in the cell-cycle distribution, while autophagy was predominantly activated in TVBF-7 cells. Conclusion: Our results give support to the role of progesterone in ACC. The involvement of its analog (megestrol acetate) in reducing ACC progression in ACC patients undergoing EDP-M therapy is now under investigation in the PESETA phase II clinical study. Full article
(This article belongs to the Special Issue From Molecular Insights to Novel Clinical Perspectives in Adrenocortical Cancer)
►▼ Show Figures

Graphical abstract

15 pages, 1926 KiB  
Article
Steroidogenic Factor 1, a Goldilocks Transcription Factor from Adrenocortical Organogenesis to Malignancy
by Lauriane Relav, Mabrouka Doghman-Bouguerra, Carmen Ruggiero, João C. D. Muzzi, Bonald C. Figueiredo and Enzo Lalli
Int. J. Mol. Sci. 2023, 24(4), 3585; https://doi.org/10.3390/ijms24043585 - 10 Feb 2023
Cited by 7 | Viewed by 1998
Abstract
Steroidogenic factor-1 (SF-1, also termed Ad4BP; NR5A1 in the official nomenclature) is a nuclear receptor transcription factor that plays a crucial role in the regulation of adrenal and gonadal development, function and maintenance. In addition to its classical role in regulating the expression [...] Read more.
Steroidogenic factor-1 (SF-1, also termed Ad4BP; NR5A1 in the official nomenclature) is a nuclear receptor transcription factor that plays a crucial role in the regulation of adrenal and gonadal development, function and maintenance. In addition to its classical role in regulating the expression of P450 steroid hydroxylases and other steroidogenic genes, involvement in other key processes such as cell survival/proliferation and cytoskeleton dynamics have also been highlighted for SF-1. SF-1 has a restricted pattern of expression, being expressed along the hypothalamic-pituitary axis and in steroidogenic organs since the time of their establishment. Reduced SF-1 expression affects proper gonadal and adrenal organogenesis and function. On the other hand, SF-1 overexpression is found in adrenocortical carcinoma and represents a prognostic marker for patients’ survival. This review is focused on the current knowledge about SF-1 and the crucial importance of its dosage for adrenal gland development and function, from its involvement in adrenal cortex formation to tumorigenesis. Overall, data converge towards SF-1 being a key player in the complex network of transcriptional regulation within the adrenal gland in a dosage-dependent manner. Full article
(This article belongs to the Special Issue From Molecular Insights to Novel Clinical Perspectives in Adrenocortical Cancer)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop